Evidence map›Paper›PMID 41864345›Full record

ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance

Sotatercept improves right ventricular function but is associated with new or worsening pericardial effusions: a cardiovascular magnetic resonance study in intermediate-high risk pulmonary arterial hypertension.

Ruta Virsinskaite, Catherine J Beattie, Nina Karia, Tushar Kotecha, Benjamin E Schreiber, Jay Suntharalingam, Robert V MacKenzie Ross, Philip D Hughes, Julian Lentaigne, Ann M Scott-Russell and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ruta VirsinskaiteNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK; Department of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Institute of Cardiovascular Science, University College London, London, UK.
Catherine J BeattieDepartment of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Institute of Cardiovascular Science, University College London, London, UK.
Nina KariaNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK; Institute of Cardiovascular Science, University College London, London, UK.
Tushar KotechaNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK; Department of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Institute of Cardiovascular Science, University College London, London, UK.
Benjamin E SchreiberNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK.
Jay SuntharalingamDepartment of Respiratory Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Robert V MacKenzie RossDepartment of Respiratory Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Philip D HughesDepartment of Respiratory Medicine, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Julian LentaigneDepartment of Respiratory Medicine, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Ann M Scott-RussellDepartment of Rheumatology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
Victoria ParishDepartment of Cardiology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Ganesh KasavkarDepartment of Rheumatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Bianca DumitruDepartment of Rheumatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Gavin ThomasDepartment of Cardiology, Ulster Hospital, Belfast, Northern Ireland, UK.
Marianna FontanaDepartment of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Division of Medicine, University College London, London, UK.
Vivek MuthuranguInstitute of Cardiovascular Science, University College London, London, UK.
J Gerry CoghlanNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK.
Daniel S KnightNational Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK; Department of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Institute of Cardiovascular Science, University College London, London, UK. Electronic address: dan.knight@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSotatercept is a novel drug therapy for pulmonary arterial hypertension (PAH) that significantly reduces clinical worsening and improves exercise capacity, functional class, and pulmonary haemodynamics. This study aims to use cardiovascular magnetic resonance (CMR) to monitor the cardiac response to sotatercept in patients with PAH.

methodsPatients with PAH at intermediate-high or high mortality risk and already on background maximal triple PAH therapies, including parenteral prostacyclin analog for at least 3 months, were offered enrollment to a patient access program for sotatercept at the Royal Free Hospital National Pulmonary Hypertension Service. Baseline and follow-up CMR studies were performed at a median interval of 24 (interquartile range 6) weeks.

resultsEighteen out of 23 patients enrolled in the sotatercept access program underwent baseline and follow-up CMR studies (3 patients paused or discontinued sotatercept prior to 12 weeks; 2 patients were unable to undergo CMR). All 18 patients were stratified as being of intermediate-high mortality risk. Significant improvements were observed in right ventricular (RV) size (RV end-diastolic volume -34±30 mL, p = 0.0023; RV end-systolic volume -27 ± 29 mL, p = 0.0023), RV mass (Z = -2.63, p = 0.016), RV function (RV ejection fraction 5 ± 8%, p = 0.034) and right atrial size (-6 ± 4 cm

conclusionCMR tracks improvements in right heart chamber size, mass, and function along with metrics of RV afterload in patients with PAH receiving sotatercept. The improvements in RV size and function met or exceeded the clinically relevant minimally important differences for these CMR-derived metrics in patients with PAH. Routine interval surveillance with CMR in patients receiving sotatercept will also enable surveillance for the off-target finding of new-onset or worsening pericardial effusions.

Indexed as

Antihypertensive AgentsArterial PressureMagnetic Resonance Imaging, CinePericardial EffusionPulmonary Arterial HypertensionRecombinant Fusion ProteinsVentricular Function, RightAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesAntihypertensive AgentsRecombinant Fusion ProteinsCardiovascular magnetic resonancePericardial effusionPulmonary arterial hypertensionRight ventricular ejection fractionRight ventricular functionSotatercept

Identifiers

PMID41864345
PMCPMC13241712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.